Contact Us marketing@medicilon.com
Medicilon Logo
|
search icon search icon 中 contact icon menu icon
Medicilon Logo
|
search icon close search icon 中 contact icon menu icon
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
Over 20 years of experience in R&D
Learn more
01 Drug Discovery
Chemistry Research
Biology Research
Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates
Active Pharmaceutical Ingredients
Pharmaceutical preparation
Analytical Method Development and Quality Control
CMC Filings
Analytical Testing Center
03 Preclinical Research
Pharmacology & Pharmacodynamics
Drug Safety Evaluation
DMPK
Bioanalysis
IND Filings
01 One-stop Integrated Services
Liposome Drug Development
Drug Discovery
Pharmaceutical Research
Preclinical Research
Botanical Drug Preclinical R&D
02 Innovative Drug Services
ADC
PROTAC
mRNA Vaccine
Cellular Immunotherapies
Nucleic Acid Drug
Peptide Drug Conjugate (PDC)
Antibody
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection
Metabolite Identification (MetID)
Drug Forming Research
Flow Cytometry Technology
SEND Format Conversion
Flow Sorting
NanoString nCounter Detection
Routes of Drug Administration
04 Drug Efficacy Evaluation for Common Diseases
IO Pharmacodynamic Model
Inflammatory and Immune Diseases
Rodent Cerebrovascular Disease
05 Advanced Preparation R&D
Inhalation drug
Ophthalmic drug
Skin Topical Preparation
06 Targeted Drugs R&D Services
STAT3-targeted Drugs R&D Service
GLP-1 New Drug R&D Service
KRAS-targeted Drugs R&D Service
CAREERS
Talent Development
Campus Recruitment
Recruitment
Campus Recruitment
Campus Recruitment
Recruitment
Recruitment
News
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
2024-07-22Medicilon Events
The Shanghai Overseas Returned Scholars Association invites the Dutch PhD delegation to visit Medicilon, exploring paths for innovative development together
On July 4th, the Shanghai Overseas Returned Scholars Association invited the Dutch PhD delegation to visit the Chuansha campus of Shanghai Medicilon Inc. (Medicilon) and held discussions with Medicilon's Founder and CEO, Chunlin Chen, among others.
Learn more
2024-07-22Medicilon Events
5th consecutive win! Medicilon once again made the list of "Top 20 Chinese R&D CRO Enterprises in 2024"
Medicilon stood out among hundreds of pharmaceutical enterprises and was honored with the "Top 20 Chinese R&D CRO Enterprises in 2024" award.
Learn more
INVESTORS
Stock Information
Investment Contact
Medicilon 688202
RMB

As of Beijing time The data is from a third-party organization and is only for reference.

For actual information, please refer to：www.eastmoney.com

CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
U.S.

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(626)986-9880

UK

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954

Email: marketing@medicilon.com

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Close

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3

Shanghai Public Network Security File No. 31011502018888 | Website Map

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888|Website Map
关闭
中
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
News and Events
Medicilon Events Featured Stories Market Events Videos A.C.E.
HomenewsFeatured Stories

Featured Stories

Hot information：
Top 10 Global CDMO Enterprises| The Meaning of IND, NDA and ANDA| Top 10 Global Clinical Research Organizations in 2021
Apr 29,2021
Research on new anti-tumor therapy targeting MCL1 protein in melanoma
Myeloid cell leukemia-1 (myeloidcellleukemia-1, Mcl-1) is a protein that is highly expressed in cervical cancer, liver cancer, lymphoma, lung cancer and other tumor tissues. It can directly regulate cell differentiation and cell cycle. The occurrence and development are closely related. Recombinant protein expression and protein purification research can lay the foundation for studying the biologicalRead more
More
Research on new anti-tumor therapy targeting MCL1 protein in melanoma
Apr 28,2021
PDK4 gene can be used as a biomarker for the treatment of prostate cancer
In the development of anti-cancer drugs, many researchers have been paying attention to finding special genetic markers to help identify those patients with prostate cancer that are more prone to worsening and those who can successfully use drug treatment or respond well, trying to find a relationship with prostate cancer. New genetic biomarkers related toRead more
More
PDK4 gene can be used as a biomarker for the treatment of prostate cancer
Apr 28,2021
Gateway technology, the technology of constructing insect cell expression vector
In order to improve the high-level and soluble expression of recombinant protein, a protein expression system can be constructed. The baculovirus vector expression system is an efficient eukaryotic expression system that can use baculovirus as a carrier for foreign genes to express foreign proteins by infecting insect cells. Gateway technology is a very convenient vectorRead more
More
Gateway technology, the technology of constructing insect cell expression vector
Apr 28,2021
Research found: RBBP8 gene mutation is a key factor in young women suffering from breast cancer
The human CtIP gene, also known as RBBP8, is located on the long arm 11.2 of chromosome 18 and can encode the CtIP protein. There are many studies on CtIP protein, and the relationship between it and tumor pathogenesis is constantly being recognized. Mutations of CtIP protein can be found in a variety of humanRead more
More
Research found: RBBP8 gene mutation is a key factor in young women suffering from breast cancer
Apr 28,2021
Lowry method for quantitative detection of protein concentration
The determination of protein content is one of the important indicators for the quality control of biotechnology drugs. Lowry method is a classic method for quantitative determination of protein content, which is widely used and suitable for identifying the purification effect of protein and carrying out activity determination. Lowry method and BCA method can beRead more
More
Lowry method for quantitative detection of protein concentration
Apr 28,2021
LYTAC technology, a lysosomal degradation technology
Targeted protein degradation is an emerging direction in the field of drug development. 40% of human genes encode extracellular proteins or membrane proteins. The degradation of cell membrane proteins is usually accomplished through lysosomal pathways. lysosome targeting chimeras lytacs (Lytac technology) are an innovative technology that degrades cell membrane or extracellular proteins, enabling degradation ofRead more
More
Apr 27,2021
ADC research and development are normalizing, but Pfizer "quietly” changed hands to others!
On March 18, Pfizer and American biotechnology company Pyxis Oncology (hereinafter referred to as "Pyxis”) jointly announced that the two parties have reached a global licensing agreement for two ADC (antibody-drug conjugate) candidate products, but specific transactions The amount was not disclosed. According to the license agreement, Pfizer will provide Pyxis with worldwide licensing, developmentRead more
More
ADC research and development are normalizing, but Pfizer "quietly” changed hands to others!
Apr 27,2021
The main points of clinical use of 8 ADC drugs
Antibody-Drug Conjugate (ADC) is a class of targeted biological agents that conjugate target-specific monoclonal antibodies to highly lethal cytotoxic drugs through a specific connector.Small molecule cytotoxic drugs can be efficiently delivered to target tumor cells by using monoclonal antibodies as the carrier.
More
The main points of clinical use of 8 ADC drugs
Apr 26,2021
The first CD19 targeting ADC drug is approved, who is leading the ADC market?
A few days ago,ADC Therapeutics SA announced that the FDA has approved its antibody-conjugated drug Zynlonta (loncastuximab tesirine-LPYL) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (R/ R DLBCL) who have previously received 2-line or more systemic therapy. Loncastuximab tesirine (Lonca, formerly known as ADCT-402) is an antibody-conjugated drug (ADC)Read more
More
The first CD19 targeting ADC drug is approved, who is leading the ADC market?
Apr 26,2021
Something you must know about the yeast two-hybrid system
Yeast two-hybrid Yeast two-hybrid, proposed by Fields in 1989, is primarily used to analyze the gene system for protein-protein interactions in yeast and is a genetic method for the module structure of transcription factors. The yeast two-hybrid system was developed in eukaryotic model yeast to study protein interactions in living cells, and weak, transient interactionsRead more
More
Something you must know about the yeast two-hybrid system
Stock Code
688202

Global

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(626)986-9880(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 62, Banpodae-ro 4-gil, Seocho-gu, Seoul, 06719 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->